Get the Stockscreener App
21.20
2.06%
-0.60
Inhibrx Biosciences Inc stock is traded at $21.20, with a volume of 38,040.
It is down -2.06% in the last 24 hours and up +30.74% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$21.80
Open:
$21.88
24h Volume:
38,040
Relative Volume:
0.36
Market Cap:
$306.74M
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.1786
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-12.00%
1M Performance:
+30.74%
6M Performance:
+57.45%
1Y Performance:
+71.62%
1-Day Range:
$20.95
$23.03
1-Week Range:
$20.95
$24.81
52-Week Range:
$10.80
$25.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
21.19 | 312.68M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.84 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.10 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
689.63 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
309.50 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences Inc. stock trend outlook and recovery pathPredictable Return Strategy with AI Support - Newser
What’s the recovery path for long term holders of Inhibrx Biosciences Inc.Entry Timing Tracker with Alert Accuracy - Newser
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionTrend Analysis for Safer Market Entries - Newser
Visual trend scoring systems applied to Inhibrx Biosciences Inc.Chart Risk Profile for Capital Preservation - Newser
Combining price and volume data for Inhibrx Biosciences Inc.Capital Growth Plan for New Investors - Newser
Risk adjusted return profile for Inhibrx Biosciences Inc. analyzedBuy Point Strategy with Profit Protection - Newser
Tools to assess Inhibrx Biosciences Inc.’s risk profileFree Buy Alerts With Low Risk Confirmation - Newser
What are analysts’ price targets for Inhibrx Biosciences Inc. in the next 12 monthsIdentify winners with top-tier analysis - Jammu Links News
Inhibrx Biosciences Inc. Reversal Rally May Surprise BearsExit Ready Momentum Stock Watchlist Expanded - metal.it
Will Inhibrx Biosciences Inc. outperform the marketFree Community Entry Consensus Trade Ideas - Newser
Inhibrx Biosciences Inc. stock prediction for this weekFree Earnings Play Trade Plan With Alerts - Newser
Inhibrx Biosciences Inc. Stock Analysis and ForecastAccelerated capital growth - Jammu Links News
What makes Inhibrx Biosciences Inc. stock price move sharplyRemarkable growth - Jammu Links News
What analysts say about Inhibrx Biosciences Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
Does Inhibrx Biosciences Inc. stock perform well during market downturnsTriple-digit wealth increases - Jammu Links News
Is Inhibrx Biosciences Inc. stock overvalued or undervaluedAmplify your gains with low-risk picks - Jammu Links News
Does Inhibrx Biosciences Inc. qualify in momentum factor screeningLow Risk Stock Trade Opportunity Analysis - Newser
What moving averages say about Inhibrx Biosciences Inc.2-Day Signal Watch with Forecast Outcome - Newser
Inhibrx Biosciences Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Stock Market Strategy Summary - Newser
What is the risk reward ratio of investing in Inhibrx Biosciences Inc. stockConsistent high-performance stocks - Jammu Links News
New Product Launches: Will They Boost Inhibrx Biosciences Inc. Stock in 2025Momentum-Based Prediction for Quick Returns - Newser
What are Inhibrx Biosciences Inc. company’s key revenue driversNavigate market shifts with confidence - Jammu Links News
Should I hold or sell Inhibrx Biosciences Inc. stock in 2025Robust investment performance - Jammu Links News
When is Inhibrx Biosciences Inc. stock expected to show significant growthCapitalize on market momentum for profits - Jammu Links News
What institutional investors are buying Inhibrx Biosciences Inc. stockGet alerts on high-potential market moves - Jammu Links News
Has Inhibrx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewStrategy Builder for Growth Focused Traders - Newser
Published on: 2025-08-01 16:27:04 - metal.it
How does Inhibrx Biosciences Inc. compare to its industry peersFinancial News Tips To Watch Now - Jammu Links News
Intrinsic Value of Inhibrx Biosciences Inc. Stock: Is It Undervalued or OvervaluedBuy Strategy with Smart Exit Timing - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilityIn-Depth Stock Trading Volume Analysis - Newser
Sectors Driving Future Growth for Inhibrx Biosciences Inc. StockLong-Term Allocation Strategy Summary Breakdown - Newser
Reversal indicators forming on Inhibrx Biosciences Inc. stockEarly Entry Planner for Swing Candidates - Newser
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):